Amgen Terminates Collaboration Agreement for Rocatinlimab with Kyowa Kirin
AMGN sits 30% above its 52-week low of $261.43.
Summary
Amgen Inc. has terminated its License and Collaboration Agreement with Kyowa Kirin Co., Ltd. for the research, development, and commercialization of rocatinlimab, transferring all responsibilities for the product to Kyowa Kirin.
Key Events · M&A and Partnerships · AMGN
-
Collaboration Agreement Terminated
Amgen Inc. and Kyowa Kirin Co., Ltd. mutually agreed to terminate their License and Collaboration Agreement, dated June 1, 2021, for the research, development, and commercialization of rocatinlimab (KHK4083/AMG 451).
-
Product Responsibilities Transferred
Amgen will discontinue its participation in the rocatinlimab program, with all activities, including development, manufacturing, medical affairs, regulatory, and commercialization, transferring to Kyowa Kirin.
-
Strategic Pipeline Adjustment
The termination indicates a strategic adjustment in Amgen's pipeline, removing rocatinlimab as a future potential asset from its portfolio.
-
Regulatory Approval Pending
The termination will become effective upon receipt of regulatory approval, with a Transition Agreement concurrently entered into to facilitate the transfer of activities.
Analysis · AMGN · Life Sciences
This 8-K filing signals a strategic shift for Amgen as it exits the rocatinlimab program, transferring full control and responsibility to Kyowa Kirin. While the financial impact is not disclosed, the termination of a collaboration for a specific drug candidate, even for a large pharmaceutical company like Amgen, represents a change in its pipeline and future revenue potential from that asset. Investors will likely view this as a deprioritization of rocatinlimab by Amgen, potentially freeing up resources for other programs but also removing a potential asset from its portfolio. The market will watch for further details on the strategic rationale and any implications for Amgen's broader pipeline strategy.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMGN was trading at $340.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.7B. The 52-week trading range was $261.43 to $353.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.